Q BioMed Inc CEO Denis Corin says a new study that shows the superior safety and efficacy of its Uttroside-B chemotherapeutic versus FDA-approved drug Sorafenib adds weight to the promise of an effective therapeutic for a patient population that desperately needs better and more treatment options.
Corin told Proactive that the study provides additional data for Q BioMed to present to potential partners.
“Our objective with this asset has always been to develop it and hopefully partner it with large pharma who are interested in this space,” Corin added.
source
